* 本报告来自网络，如有侵权请联系删除
中国医药研发趋势——本地化发展的机遇与影响
收藏
分享
纠错
价格免费
数据简介
The growing local RSD industry is already challengingtraditional, global-centric RED models with increasedR&D competition and regulatory complexities. Despitethe long-term promise of accelerated time-to-market formore innovative products, large uncertainties still remain intiming and the extent of impacts.
详情描述
As China's government continues to face gaps in the quality of and access to healthcare—in addition to the growingburdens of population size, ageing and utilization on the existing system—one strategy will be continued support for thelocal RGD industry. The primary directives of this strategy are to develop innovative capabilities and upgrade applicabletechnologies as well as attract, develop and retain a strong talent base.This strategy will have strong implications formultinational pharmaceutical companies, who must adopt more localized RED approaches to address new opportunitiesand challenges.Opportunities do exist,however, for MNC pharma to adopt a more localized andintegrated R&D strategy in China.This strategy wouldleverage increased local RSD capabilities in order toaccelerate development of local, and in the longer-term,global products.
报告预览
*本报告来自网络，如有侵权请联系删除
相关「可视数据」推荐
相关「数据报告」推荐
